Eli Lilly's acquisition spree shows no sign of stalling, although the Big Pharma is keeping the terms of its latest buy pretty vague. This time, Lilly has returned to antibody-drug conjugates (ADCs), ...

Eli Lilly LLY.N said on Thursday its newly approved obesity pill was not inferior to a widely used long-acting insulin at lowering the risk of major heart problems in patients with type 2 diabetes and ...

Eli Lilly’s LLY0.57%increase; green up pointing triangle late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results. Achieve-4, the longest phase 3 ...

Eli Lilly’s LLY0.66%increase; green up pointing triangle Foundayo weight-loss pill is now available in the U.S. following the Food and Drug Administration’s approval earlier this month, the company ...

Wall Street impressed with initial prescriptions for Lilly's Foundayo Lilly cautions early weekly figures may not be fully comprehensive Demand for Novo Nordisk's oral Wegovy also strong April 17 ...

Eli Lilly has chalked up another victory in the chronic lymphocytic leukemia (CLL) space, as its BTK inhibitor Jaypirca delivered its fourth positive phase 3 readout in the blood cancer. Monday, Lilly ...

Eli Lilly is wasting no time in pursuit of the next indication for its newly christened obesity pill Foundayo, presenting new data in diabetes Thursday that also serve to address the FDA’s desire for ...

Eli Lilly's newer weight-loss medicines will help cement its dominance in the market. The company could ride this tailwind through the medium term and deliver strong returns. Second, Eli Lilly's newer ...

Eli Lilly (LLY) reported Q4 revenue of $19.29B up 42.6% YoY, with Mounjaro generating $7.41B (up 110%) and Zepbound adding $4.26B (up 123%). Novo Nordisk (NVO) posted Q4 revenue down 7.6% YoY and cut ...

Eli Lilly & Co. said its new weight-loss pill Foundayo was at least as good as an older insulin at warding off heart attacks, strokes or other major cardiovascular events in a study, a finding that ...

The Food and Drug Administration is asking Eli Lilly to gather more safety data on its new weight loss pill, Foundayo, including whether it could be linked to liver and heart problems, according to ...